Ligand Pharmaceuticals Incorporated (LGND) Q4 2021 Earnings Results

Ligand Pharmaceuticals Beats on EPS, Stock Down 8.43%

Ligand Pharmaceuticals reported a strong earnings per share figure, significantly beating expectations. However, the stock fell by 8.43% in reaction, likely due to the absence of revenue details and future guidance. Investors may be cautious as they await more comprehensive financial information in future reports.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$1.80	N/A	+85.57%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Neutral

Management maintained a neutral tone during the earnings call, focusing on long-term growth strategies. They did not provide specific guidance or revenue figures.

Management did not provide specific revenue figures or guidance for the upcoming quarters.

The company expressed confidence in its long-term strategy despite the lack of detailed financials.

Ligand Pharmaceuticals Beats on EPS, Stock Down 8.43%

Key numbers

Management commentary

Ligand Pharmaceuticals Incorporated

More earnings this week

Ligand Pharmaceuticals Beats on EPS, Stock Down 8.43%

Key numbers

Management commentary